Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Read more about Astellas and Drais Partner To Develop Astellas Compound through Telsar
Tokyo, March 30, 2012 - Astellas Pharma Inc. (“Astellas Pharma”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) announced that Kiklin® Capsules (development code: ASP1585, generic...
Tokyo, March 29, 2012 – Pfizer Japan Inc. (“Pfizer”) and Astellas Pharma Inc. (“Astellas”) today announced that the companies have agreed to continue and expand their excellent...
Read more about Pfizer and Astellas Announce Agreement to Amend Licensing Agreement for Lipitor
SAN DIEGO & TOKYO, JAPAN, March 29, 2012—Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) and Tokyo-based Astellas Pharma Inc. (Tokyo: 4503) announced today the execution of an exclusive...
Staines, 27th March 2012. ASTELLAS PHARMA EUROPE Ltd., the European subsidiary of Tokyo – based Astellas Pharma Inc.(Tokyo:4503) today announced the submission of a Market Authorisation...
Astellas Pharma Inc. (TSE:4503; Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka; ”Astellas”) and UMN Pharma Inc. (Headquarters, Akita; CEO, Shu-ichi Kanazashi; ”UMN”) today...
Sanofi (Headquarters: Paris, France) and Astellas Pharma Inc. (Headquarters: Tokyo, President and CEO: Yoshihiko Hatanaka) announced today that the two companies agreed to dissolve sanofi-aventis...
Read more about Sanofi and Astellas to dissolve sanofi-aventis Yamanouchi Pharmaceutical Inc.
Tokyo, February 20, 2012 - Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and Sanwa Kagaku Kenkyusho Co., Ltd. (“SKK”; Headquarters: Nagoya;...
Astellas and UCB partner to bring certolizumab pegol to rheumatoid arthritis patients in Japan UCB files certolizumab pegol for marketing authorisation with the Japanese Ministry of Health, Labour...
Tokyo, Japan, January 19, 2012 – The Astellas Asia-Oceania Foundation announced that it donated U.S. dollar 20,000 to the Philippine Urological Association for relief efforts in the Philippines...
Read more about Astellas Asia-Oceania Foundation Supports Philippine Typhoon Relief Efforts
TOKYO, JAPAN and SANTA CLARA, CA - January 17, 2012 - Astellas Pharma Inc. (Tokyo: 4503) and XenoPort, Inc. (NASDAQ: XNPT) announced today that Regnite® (gabapentin enacarbil) has received...
Tokyo, January 5, 2012 – Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announces that it will halt exports of Gaster-D 20mg tablets to Korea for a period of three months in accordance with a...
Read more about Temporary Halt of Gaster-D 20mg Tablet Exports to Korea
SAN DIEGO, Calif. and Deerfield, Ill., December 21, 2011 — Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous...
Tokyo, December 9, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced that the Ireland Japan Chamber of Commerce (IJCC, http://www.ijcc.jp/) presented it with a business...
Tokyo, November 11, 2011 - Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) today announced the receipt of a letter from the U.S. Food and Drug Administration (FDA) indicating that it accepted...
Read more about Receipt of Filing Communication Letter from U.S. FDA Regarding Mirabegron (YM178)
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the recombinant influenza HA vaccine (H5N1) ASP7373 (former code:...
Tokyo, Japan, November 11, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced today that it is signing the United Nations Global Compact1, which will further reinforce the...
Read more about Astellas Signs United Nations Global Compact
Tokyo, Japan, October 28, 2011 – The Astellas Asia-Oceania Foundation announced that it will make a donation of USD $20,000 to the Thai Red Cross Society to assist with relief efforts after the...
Read more about The Astellas Asia-Oceania Foundation Supports Thai Flood Relief Efforts
Tokyo, Japan, October 17, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced that the Societe Internationale d’Urologie (SIU) presented its senior science advisor (and former...
Read more about Astellas' Senior Science Advisor Receives "Distinguished Partner Award" from SIU
Tokyo, September 28, 2011 -Astellas Pharma Inc. (Tokyo:4503, “Astellas”) announced that it has decided to discontinue the global development of darexaban maleate (generic name, development...
Astellas Pharma Inc. (Headquarters, Tokyo; President & CEO, Yoshihiko Hatanaka) today announced that the administration of the seasonal influenza HA vaccine ASP7374 (former code: UMN-0502) was...
Astellas Pharma Inc. (“Astellas Pharma”; Headquarters: Chuo-ku, Tokyo; President and CEO: Yoshihiko Hatanaka) and sanofi-aventis K.K. (“sanofi-aventis”; Headquarters: Shinjuku-ku, Tokyo;...
Read more about Transfer of Distribution Rights for Targocid® and Maalox®
Tokyo, Japan, September 7, 2011 - Astellas Pharma Inc. (Tokyo:4503,“Astellas”) announced the donation of three high-standard ambulances to local municipalities in Japan. The numbers of calls...
Read more about Astellas: Donation of Ambulances on First-Aid Day (September 9)
Tokyo & Sapporo, Japan, September 5, 2011 – Evec, Inc. (”Evec”) and Astellas Pharma Inc. (Tokyo:4503, “Astellas”) today announced that they have entered into a license agreement for one...
Read more about Astellas Pharma signs a license agreement with Evec for a fully-human antibody
Tokyo, August 30, 2011 – Astellas Pharma Inc. (Tokyo: 4503, “Astellas”) announced that it has decided to sell the fixed asset listed below. 1． Details of Fixed Asset to Be Sold Asset:...
Follow us
